Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 \u2013 December 31, 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics Expands The Connection Study to Include Infants with a Birth Weight Below 750 Grams","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruitment of the Smallest Infants in the Connection Study Paused","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Next recruitment milestone reached in IBT\u2019s Phase III Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Connection Study Continues After Pre-scheduled Data Monitoring Committee (DMC) Review","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics\u2019 (IBT) Publishes Clinical Findings in The British Journal of Gastroenterology on The Convincing Association of Clinical Events to The Feeding Primary Endpoint of The \u2018Connection Study\u2019","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics\u2019 (IBT) Opening of A Final Infant Cohort Will Accelerate Patient Recruitment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IBT Continues to Recruit Prematurely Born Infants to the Connection Study Following a Planned Safety Analysis.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Infant Bacterial Therapeutics Product Receives FDA Orphan Drug Designation","therapeuticArea":"Pediatrics\/Neonatology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Pediatrics\/Neonatology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Lactobacillus Reuteri

    Menu

    Lactobacillus Reuteri

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Additional Infant Bacterial Therapeutics Product Receives FDA Orphan Drug Designation

              Details:

              IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Pediatrics/Neonatology Product Name: IBP-1016

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IBT Continues to Recruit Prematurely Born Infants to the Connection Study Following a Planned Safety Analysis.

              Details:

              IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of necrotizing entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe

              Details:

              IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Infant Bacterial Therapeutics’ (IBT) Opening of A Final Infant Cohort Will Accelerate Patient Recruitment

              Details:

              IBP-9414 for the prevention of necrotizing enterocolitis contains the active substance lactobacillus reuteri, known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. It is a co-evolved human bacterial strain naturally present in breast milk.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Infant Bacterial Therapeutics’ (IBT) Publishes Clinical Findings in The British Journal of Gastroenterology on The Convincing Association of Clinical Events to The Feedin...

              Details:

              IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for gastroschisis (a severe and rare disease affecting infants), to prevent ROP and to prevent antibiotic resistant hospital acquired infections.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scioto Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder

              Details:

              Top-line results from the study demonstrated that SB-121 (Lactobacillus Reuteri), represents the first clinical validation of ABT platform was safe and well tolerated.

              Lead Product(s): Lactobacillus Reuteri,Sephadex,Maltose

              Therapeutic Area: Neurology Product Name: SB-121

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The Connection Study Continues After Pre-scheduled Data Monitoring Committee (DMC) Review

              Details:

              IBP-9414 (lactobacillus Reuteri), strain-specific attributes which affect the NEC pathogenesis is world’s first approved probiotic drug with the goal to prevent life-threatening diseases in premature infants.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Next recruitment milestone reached in IBT’s Phase III Study

              Details:

              IBT’s Clinical Phase III study of the drug candidate IBP-9414 for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in premature infants, the Connection Study.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Recruitment of the Smallest Infants in the Connection Study Paused

              Details:

              IBT is currently developing the drug candidate IBP-9414. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Infant Bacterial Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Infant Bacterial Therapeutics Expands The Connection Study to Include Infants with a Birth Weight Below 750 Grams

              Details:

              IBT is developing the drug candidate IBP-9414, contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk, for the prevention of necrotizing enterocolitis and improvement of feeding tolerance in premature infants.

              Lead Product(s): Lactobacillus Reuteri

              Therapeutic Area: Gastroenterology Product Name: IBP-9414

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY